Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism
Primary Purpose
Adenoma
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
complier device
Sponsored by
About this trial
This is an interventional diagnostic trial for Adenoma focused on measuring blood pressure, antihypertensive treatments
Eligibility Criteria
Inclusion Criteria:
- patients with a surgically correctable primary aldosteronism due to an aldosterone producing adenoma or an unilateral adrenal hyperplasia
- primary aldosteronism demonstrated by hormonal essays
- hight resolution adrenal CT scan
- operative decision based on the usual criteria of the different referent centers
Exclusion Criteria:
- patient's refusal to undergo the surgery or to participate in the study
- the patients with PA due to bilateral adrenal hyperplasia or with idiopathic primary aldosteronism, and patients with a biochemical diagnosis of PA without evidence for a lateralized aldosterone excess.
Sites / Locations
- CHU Toulouse
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
complier device
Arm Description
Outcomes
Primary Outcome Measures
Responders to surgery, patients not receiving aldosterone antagonists, with mean-24h-ABP < 130/80 mmHg with or without antihypertensive treatment
Secondary Outcome Measures
Day-time and night-time ABP and circadian BP variability, number of antihypertensive agents at 1 year after surgery, prediction of post-operative complications, prediction of cardiovascular morbidity at 1 year.
Full Information
NCT ID
NCT01190501
First Posted
August 25, 2010
Last Updated
February 21, 2017
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT01190501
Brief Title
Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism
Official Title
Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
June 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Our main objective is to assess whether aortic stiffness is a predictor of blood pressure response after surgery in patients with an aldosterone producing adenoma or a unilateral adrenal hyperplasia.
Detailed Description
Secondary objectives are to investigate whether aortic stiffness predicts cardiovascular , operative and postoperative morbid-mortality at 1 year, to evaluate the benefit of adrenalectomy in patients with primary aldosteronism due to unilateral adrenal hyperplasia and in patients with aldosterone producing adenoma associated with controlateral adrenal morphological abnormalities, and to participate to a national DNA repository of patients with primary aldosteronism.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adenoma
Keywords
blood pressure, antihypertensive treatments
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
96 (Actual)
8. Arms, Groups, and Interventions
Arm Title
complier device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
complier device
Intervention Description
The procedure of use of complier has to follow the recommendations for standardization of subject conditions.
Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites.
Primary Outcome Measure Information:
Title
Responders to surgery, patients not receiving aldosterone antagonists, with mean-24h-ABP < 130/80 mmHg with or without antihypertensive treatment
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Day-time and night-time ABP and circadian BP variability, number of antihypertensive agents at 1 year after surgery, prediction of post-operative complications, prediction of cardiovascular morbidity at 1 year.
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with a surgically correctable primary aldosteronism due to an aldosterone producing adenoma or an unilateral adrenal hyperplasia
primary aldosteronism demonstrated by hormonal essays
hight resolution adrenal CT scan
operative decision based on the usual criteria of the different referent centers
Exclusion Criteria:
patient's refusal to undergo the surgery or to participate in the study
the patients with PA due to bilateral adrenal hyperplasia or with idiopathic primary aldosteronism, and patients with a biochemical diagnosis of PA without evidence for a lateralized aldosterone excess.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bernard Chamontin, MD
Organizational Affiliation
CHU Toulouse
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Pierre-François Plouin, MD
Organizational Affiliation
APHP-HEGP
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Philippe Gosse, MD
Organizational Affiliation
CHU Bordeaux
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jean-Philippe Baguet, MD
Organizational Affiliation
CHU Grenoble michalon
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pierre Lantelme, MD
Organizational Affiliation
Hospices de Lyon
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xavier Girerd, MD
Organizational Affiliation
APHP-Pitié Salpêtrière
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Claire Mounier-Vehier, MD
Organizational Affiliation
CHR Lille
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yves Resnik, MD
Organizational Affiliation
CHU caen Côte de Nacre
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Toulouse
City
Toulouse
ZIP/Postal Code
31059
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism
We'll reach out to this number within 24 hrs